These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 1923913)
21. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA; Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012 [TBL] [Abstract][Full Text] [Related]
22. Reduction in the plasma clearance rate of warfarin induced by cimetidine. Bell WR; Anderson KC; Noe DA; Silver BA Arch Intern Med; 1986 Dec; 146(12):2325-8. PubMed ID: 3778066 [TBL] [Abstract][Full Text] [Related]
23. [Comparison of Quick/INR values of whole capillary blood (CoaguChek Plus) and venous citrate plasma in patients with and without oral anticoagulation]. Burri S; Demarmels Biasiutti F; Lämmle B; Wuillemin WA Schweiz Med Wochenschr; 1998 Oct; 128(44):1723-9. PubMed ID: 9846345 [TBL] [Abstract][Full Text] [Related]
24. [Optimum anticoagulation control after bileaflet mechanical valve replacement: a prospective multi-institutional study]. Kitamura M; Koyanagi H; Kawada S; Hosoda Y; Kurosawa H; Takeuchi Y; Kawase M; Wanibuchi Y Kyobu Geka; 1999 Nov; 52(12):1001-4. PubMed ID: 10554485 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Anderson DR; Harrison L; Hirsh J Arch Intern Med; 1993 Jun; 153(12):1441-7. PubMed ID: 8512435 [TBL] [Abstract][Full Text] [Related]
26. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK). Cosmi B; Palareti G; Carpanedo M; Pengo V; Biasiolo A; Rampazzo P; Morstabilini G; Testa S Haematologica; 2000 Aug; 85(8):826-31. PubMed ID: 10942929 [TBL] [Abstract][Full Text] [Related]
27. Standardizing the prothrombin time. Calibrating coagulation instruments as well as thromboplastin. Becker DM; Humphries JE; Walker FB; DeMong LK; Bopp JS; Acker MN Arch Pathol Lab Med; 1993 Jun; 117(6):602-5. PubMed ID: 8503731 [TBL] [Abstract][Full Text] [Related]
29. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience]. Míka P; Behounek J; Skoták M; Nevsímal L Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102 [TBL] [Abstract][Full Text] [Related]
30. Warfarin and heparin interaction with prostacyclin-like activity generated by arterial wall in the rat. Doni MG; Piva E Thromb Haemost; 1983 Jun; 49(3):228-9. PubMed ID: 6348997 [TBL] [Abstract][Full Text] [Related]
31. Warfarin sensitivity after mechanical heart valve replacement. Rose JP; Rihn TL; Long SF Pharmacotherapy; 1998; 18(4):856-9. PubMed ID: 9692661 [TBL] [Abstract][Full Text] [Related]
32. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Douketis JD; Johnson JA; Turpie AG Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166 [TBL] [Abstract][Full Text] [Related]
33. Multicenter evaluation of six methods for predicting warfarin maintenance-dose requirements from initial response. Sawyer WT; Poe TE; Canaday BR; Weiner JS; Williams DM; Webb CE; Ellison MJ Clin Pharm; 1985; 4(4):440-6. PubMed ID: 3899472 [TBL] [Abstract][Full Text] [Related]
34. Changes in the pharmacology of warfarin during long-term administration in dogs. Covell DG; Abbrecht PH; Powers WF J Lab Clin Med; 1984 Feb; 103(2):272-83. PubMed ID: 6693797 [TBL] [Abstract][Full Text] [Related]
35. Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin. Tischenko A; Gula LJ; Yee R; Klein GJ; Skanes AC; Krahn AD Am Heart J; 2009 Aug; 158(2):252-6. PubMed ID: 19619702 [TBL] [Abstract][Full Text] [Related]
36. Comparison and evaluation of a Point-of-care device (CoaguChek XS) to Owren-type prothrombin time assay for monitoring of oral anticoagulant therapy with warfarin. Wieloch M; Hillarp A; Strandberg K; Nilsson C; Svensson PJ Thromb Res; 2009 Jul; 124(3):344-8. PubMed ID: 19423152 [TBL] [Abstract][Full Text] [Related]
37. [International normalized ratio (INR) for optimal anticoagulant therapy]. Uetsuka Y; Katsuki T; Aosaki M; Iwade K; Hashimoto A; Koyanagi H; Saito M; Yaginuma Y; Hosoda S Kokyu To Junkan; 1993 Sep; 41(9):885-90. PubMed ID: 8210749 [TBL] [Abstract][Full Text] [Related]
38. Alterations in the effects of warfarin in dogs by halofenate: an influence upon the kinetics of prothrombin. Weintraub M; Griner PF Thromb Diath Haemorrh; 1975 Nov; 34(2):445-54. PubMed ID: 1198407 [TBL] [Abstract][Full Text] [Related]
39. Laboratory evidence in support of the currently recommended therapeutic ratio for oral anticoagulant therapy. Bradlow BA; Crout FV; Stead A; Adeagbo F Hematol Pathol; 1992; 6(1):31-6. PubMed ID: 1601820 [No Abstract] [Full Text] [Related]
40. Fat emulsion effects on prothrombin time in warfarin anticoagulated patients: an in vitro study. Cotto MA; Lutomski DM; Palascak JE; Fant WK; LaFrance RJ JPEN J Parenter Enteral Nutr; 1990; 14(2):201-3. PubMed ID: 2352338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]